Find company announcements below, or check out the latest news in the right side menu.
7. December 2006
We are pleased to announce that the Board of Directors has approved the appointment of Benny D. Loft as the new Executive Vice President and Chief Financial Officer of Novozymes, replacing Per Månsson, who died on November 17.
27. November 2006
Novozymes announces that all conditions for the completion of the acquisition of GroPep Ltd. have now been fulfilled. The transaction is expected to close on December 12, 2006.
20. November 2006
It is with our deepest regret that we have to announce that Novozymes´ Executive Vice President and Chief Financial Officer, Per Månsson after a short period of illness passed away last Friday.
25. October 2006
The results for the first nine months of 2006 are highly satisfactory. Growth in operating profit and sales of 11% and 8% respectively is wholly in line with the company’s outlook. The financial outlook for 2006 is being adjusted upwards.
25. August 2006
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
22. August 2006
Denmark – Novozymes has today acquired 600,000 B shares, worth DKK 241.3 million, from Novo A/S. The transaction price is DKK 402.16 per share and has been calculated as the average market price from August 9, 2006 to August 22, 2006 in the open window, fol
14. August 2006
Novozymes takes another important step to become a leading supplier of recombinant ingredients for the biopharmaceutical industry
8. August 2006
Novozymes maintains the high earnings level. Growth in sales and operating profit of 8% and 10% respectively for the first half of 2006 is in line with the company’s outlook.
6. July 2006
As of July 6, 2006 Novozymes has completed the acquisition of Delta Biotechnology Ltd. from the Sanofi- Aventis group.
13. June 2006
Bagsvaerd – Novozymes has completed a reduction of its share capital as decided and approved at Novozymes A/S’ annual general meeting on March 1, 2006.
12. June 2006
Novozymes takes over UK company Delta Biotechnology Ltd, and thus strengthening its position in ingredients for the biopharmaceutical industry.
9. May 2006
4. May 2006
26. April 2006
Novozymes made a good start to 2006, with growth of 14% in operating profit and 11% in sales. Outlook for 2006 is maintained.
2. March 2006
The annual meeting of shareholders of Novozymes A/S was held yesterday. The annual meeting adopted the report on the company's activities over the last financial year.
22. February 2006
21. February 2006
9. February 2006
8. February 2006
In accordance with Section 28a of the Danish Securities Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
6. February 2006
3. February 2006
24. January 2006
2005 was another good year for Novozymes. Growth in both operating profit and net profit was 11% - significantly higher than expected at the beginning of the year.
20. December 2005
In connection with the Group financial statement for 2003 published on January 29, 2004, Novozymes launched a major share buy-back programme worth a total of DKK 2.5 billion over the following three to four years.
10. November 2005
In accordance with Section 37 of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B:
27. October 2005
Operating profit rose by 9%, and net profit by 14%. Outlook for operating profit, net profit and free cash flow for the year to be adjusted upwards. Share buy-backs for 2005 to be increased by DKK 200 million to DKK 1,050 million.
10. December 2013
| Copyright © 2013 Novozymes. All Rights Reserved.